Gold prices fall as geopolitical tensions ease; U.S. CPI looms
DUBLIN - Global X ETFs ICAV, an Ireland-based investment vehicle, has announced enhancements to the index methodology for its Global X Genomics UCITS ETF, effective on or about May 9, 2025, pending approval from the Central Bank of Ireland. The changes, initiated by the fund’s Index Provider, Solactive AG, aim to broaden the thematic coverage of the index by increasing the number of constituents from 40 to 50 and incorporating pre-revenue and diversified companies.
The index adjustments are designed to reflect evolving industry trends and maintain the index’s relevance and accuracy. The revised index will include an expanded classification system for companies, allowing for the inclusion of pure-play, pre-revenue, and diversified companies involved in genomics-related activities. The aggregate weight of diversified companies in the index will be capped at 10%, with an individual limit of 2% to ensure balance.
Investors are advised to consult with their investment consultant or other professional advisors for guidance on the changes. The updated supplement to the prospectus detailing these index enhancements will be available upon request from Global X ETFs ICAV.
The fund is part of Global X ETFs ICAV, authorized by the Central Bank pursuant to European regulations, and offers shares in the Global X Genomics UCITS ETF. This press release statement serves as a notification to shareholders and does not constitute a review by the Central Bank of Ireland.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.